Colorimetric based sensing of dopamine using ionic liquid functionalized drug mediated silver nanostructures

© 2020 Elsevier B.V. The present work reports the drug mediated synthesis of silver nanoparticles (AgNPs) for sensing of dopamine (biomarker Parkinson\u27s disease and others). Augmentin drug was chosen because of functionalities and aromaticity in its structure which will not only work in the synthesis of AgNPs but also enhance the electron density on nanoparticles (NPs) for better sensing properties. 1-H-3-methylimidazolium acetate ionic liquid (IL) having characteristic properties of aromaticity and conductivity were coated on to the surface of NPs to further enhance the mentioned properties. The FTIR, Raman spectroscopy and XRD analysis demonstrate the characteristic peaks assigned to AgNPs. SEM analysis shows round shaped morphology and EDX showed strong band for AgNPs. TGA analysis showed maximum degradation at 340 °C for the prepared AgNPs. The functionalized AgNPs/IL was used in sensing of dopamine. Different reaction conditions have been optimized to find the optimal performance of AgNPs/IL such as; (a) pH (b) amount of Ag/IL (c) time of incubation; (d) temperature. The response time of the proposed sensor for dopamine detection was only 4 min with a visible colorimetric change from light grey to brown color. The proposed sensor showed a wide linear range (1 × 10−8–3.6 × 10−6 M), low limit of detection 1.18 × 10−7 M, and limit of quantification 3.92 × 10−7 M with an R2 value of 0.9997. The IL capped Ag nano assembly exhibited no reactivity towards folic acid, urea, ascorbic acid, Ca+2, K+ and was successfully used to quantify dopamine in physiological sample

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial

Benzoic Acid Derivatives of <em>Ifloga spicata</em> (Forssk.) Sch.Bip. as Potential Anti-Leishmanial against <em>Leishmania tropica</em>

This study aimed to appraise the anti-leishmanial potentials of benzoic acid derivatives, including methyl 3,4-dihydroxybenzoate (compound 1) and octadecyl benzoate (compound 2), isolated from the ethnomedicinally important plant Ifloga spicata (I. spicata). Chemical structures were elucidated via FT-IR, mass spectrometry, and multinuclear (1H and 13C) NMR spectroscopy. Anti-leishmanial potentials of the compounds were assessed using Leishmania tropica promastigotes. Moreover, acridine orange fluorescent staining was performed to visualize the apoptosis-associated changes in promastigotes under a fluorescent microscope. A SYTOX assay was used to check rupturing of Leishmania promastigote cell membranes using 0.1% Triton X-100 as positive control. A DNA interaction assay was carried out to assess DNA attachment potential. AutoDock software was used to check the binding affinity of compounds with surface enzyme leishmanolysin gp63 (1LML). Both compounds exhibited considerable anti-leishmanial potential, with LD50 values of 10.40 ± 0.09 and 14.11 ± 0.11 μg/mL for compound 1 and compound 2, respectively. Both compounds showed higher binding affinity with the leishmanolysin (gp63) receptor/protease of Leishmania, as assessed using computational analysis. The binding scores of compounds 1 and 2 with target gp63 were −5.3 and −5.6, respectively. The attachment of compounds with this receptor resulted in their entry into the cell where they bound with Leishmania DNA, causing apoptosis. The results confirmed that the investigated compounds have anti-leishmanial potential and are potential substitutes as natural anti-leishmanial agents against L. tropica

Micromeria biflora mediated gold and silver nanoparticles for colourimetric detection of antibiotics and dyes degradation

The study reports on synthesis of aqueous extract mediated gold and silver nanoparticles of M. biflora (MBAuNPs and MBAgNPs) via hydrated chloroauric acid and silver nitrate salts. The nanoparticles (NPs) were produced in 1:15 (MBAuNPs) and 1:6 (MBAgNPs) ratios under sunlight displaying localized surface plasmon resonance (LSPR) peaks at 541 and 431 nm, respectively. The sizes characterized by transmission electron, scanning electron, and atomic force microscopic (SEM, TEM, AFM) techniques were respectively 26.73 nm and 53.81 nm. The subject NPs demonstrated application in the degradation of methylene blue, Congo red, Rhodamine B, methyl orange, ortho-nitrophenol, and para-nitrophenol ranging from 65 to 86 %. For detection of levofloxacin, amoxicillin, and azithromycin antibiotics, the MBAuNPs and MBAgNPs exhibited efficiency in real water and biological (blood plasma and urine) samples. Conclusively, the MBAuNPs and MBAgNPs applications for dyes degradation and antibiotics detection was found as simple and cost-effective analytical method

Acceptance rate, hesitancy and comorbidities in pregnant women: A COVID-19 vaccination status

We analyzed the electronic data (e-data) of n=5231 vaccinated candidates including n=3671 males and n=1560 females. We studied the COVID-19 vaccine brands such as Sino pharm, CanSino, SinoVac, Moderna and Pfizer. We noted adverse effects in post-vaccinated candidates were Instability in blood pressure 29.5%, Swelling 3.5%, Redness 14.2%, Itching 7.13%, and Rashes 2.4%. Comorbidities in the vaccinated candidates such as Hypertension 33%, Diabetes mellitus 17%, Kidney disease 42%, and Chronic respiratory disease 9%. COVID-19 vaccine hesitancy 1153, 22% and Non-Hesitant 4078, 77%. We analyzed the e-data of COVID-19 vaccinated candidates, the acknowledgement of COVID-19 immunization in pregnant women. Worrying about vaccine safety was the significant justification for hesitancy. Recognizing mentalities among study groups will be valuable for coming up with vaccine strategies that increment the ongoing pandemic

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

BackgroundTranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.MethodsWe did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.FindingsBetween July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).InterpretationWe found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial.</div